NCT03417544 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03417544
Title	Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Nancy Lin, MD
Indications	Her2-receptor positive breast cancer
Therapies	Atezolizumab + Pertuzumab + Trastuzumab
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 2 of 2 entries

Facility	Status	City	State	Zip	Country	Details
Dana-Farber Cancer Institute		Boston	Massachusetts	02215	United States	Details
Northwestern University		Chicago	Illinois	60611	United States	Details

Showing 1 to 2 of 2 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03417544Clinical Trial Detail